Date:1/22/2009

ts are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K/A (No. 2) for the year ended December 31, 2007 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.

To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0

    Investor Contact:
    Hayden IR
    Jeff Stanlis
    Partner and Vice President of Communications
    (602) 476-1821
    jeff@haydenir.com

'/>"/>

SOURCE NewCardio, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Dorin Panescu Named NewCardios Chief Technical Officer
2. NewCardio Management to Host Conference Call on October 21
3. Glen C. Williams Joins eLearning Sales Team for Simbionix, Heading up Chicago Office
4. Valerie DeFillipo, Reproductive Health and Rights Expert, Joins Abt Associates
5. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
6. David Bagley Joins Histogen as President
7. Biotechnology Veteran Michael Webb Joins Boston-based Investment Bank as Senior Advisor
8. Dr Stephan Rietiker Joins BioCeramic Therapeutics
9. Dr. John Stephen Osika, HIV/AIDS and Infectious Disease Expert, Joins Abt Associates
10. GEN Joins Charles Darwin 2009 Celebration
11. BioLife Solutions Joins Prestigious Biomedical Excellence for Safer Transfusion Collaborative